Status:

TERMINATED

Risk Factor Control Before Orthopedic Surgery

Lead Sponsor:

NYU Langone Health

Conditions:

Osteoarthritis

Cardiovascular Disease

Eligibility:

All Genders

21+ years

Phase:

PHASE4

Brief Summary

This trial is designed to determine the best preoperative management strategy for patients undergoing orthopedic surgery.

Detailed Description

OPTIMIZE - OS (Optimization of Pre-surgical Testing with an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events - Orthopedic Surgery) trial is to determine the best management stra...

Eligibility Criteria

Inclusion

  • • ≥ 21 years of age
  • Subjects undergoing open orthopedic surgery of the hip, knee or spine
  • Surgery is scheduled at least 3 days after PAT visit and no more than 14 days.
  • High risk subject cohort
  • Coronary artery disease, or
  • Cerebrovascular disease (prior stroke, TIA or carotid artery disease (\>70% stenosis), or
  • Peripheral artery disease, or
  • Prior Venous thromboembolism or arterial thromboembolism, or
  • Age ≥ 60 years and 2 of the following
  • Renal insufficiency (creatinine clearance \< 60ml/min)
  • Diabetes
  • COPD
  • Hypertension
  • Active smoker or stopped less than 30 days prior to consent
  • Cancer (excluding BCC)
  • Heart Failure

Exclusion

  • • Known intolerance to statins
  • Subject is already on maximum dose statin (atorvastatin/Lipitor 80mg daily or rosuvastatin/crestor 40mg daily)
  • Bilateral renal artery stenosis
  • End stage renal disease (receiving dialysis or CrCl \<30ml/min)
  • Known allergy or intolerance to ACE-inhibitor (other than cough) or Angiotensin receptor blocker (e.g. angioedema, hyperkalemia)
  • Known allergy or intolerance to beta blockers
  • Known sick sinus syndrome not treated with permanent pacemaker
  • Known greater than first degree AV block not treated with a pacemaker
  • Excessive alcohol intake
  • Acute Coronary Syndrome requiring hospitalization within 1 month
  • Stroke within 1 month
  • Known pregnancy
  • Severe co-morbid condition with life expectancy \< 6 months
  • Inability to give informed consent or adhere to follow-up as per protocol
  • Current participation in another investigational drug or device trial

Key Trial Info

Start Date :

February 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 2 2018

Estimated Enrollment :

198 Patients enrolled

Trial Details

Trial ID

NCT01837069

Start Date

February 1 2014

End Date

April 2 2018

Last Update

July 27 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

NYU Hospital for Joint Diseases

New York, New York, United States, 10003